Duality Advisers LP Purchases Shares of 12,114 Humana Inc. (NYSE:HUM)

Duality Advisers LP purchased a new stake in shares of Humana Inc. (NYSE:HUM - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 12,114 shares of the insurance provider's stock, valued at approximately $5,546,000. Humana accounts for approximately 0.6% of Duality Advisers LP's portfolio, making the stock its 23rd largest holding.

Other hedge funds also recently bought and sold shares of the company. Rakuten Securities Inc. bought a new stake in Humana during the fourth quarter valued at about $25,000. Sunbelt Securities Inc. bought a new stake in Humana during the first quarter valued at about $28,000. Gradient Investments LLC lifted its stake in shares of Humana by 200.0% in the fourth quarter. Gradient Investments LLC now owns 60 shares of the insurance provider's stock valued at $27,000 after buying an additional 40 shares during the period. Cetera Trust Company N.A bought a new stake in shares of Humana in the fourth quarter valued at about $28,000. Finally, Nvwm LLC lifted its stake in shares of Humana by 41.0% in the third quarter. Nvwm LLC now owns 86 shares of the insurance provider's stock valued at $42,000 after buying an additional 25 shares during the period. 92.38% of the stock is currently owned by institutional investors.

Humana Price Performance

Shares of NYSE HUM traded up $3.50 during mid-day trading on Friday, hitting $328.33. 1,143,745 shares of the stock were exchanged, compared to its average volume of 1,740,519. The company has a market cap of $39.61 billion, a P/E ratio of 16.57, a PEG ratio of 1.92 and a beta of 0.45. The stock's fifty day simple moving average is $330.40 and its two-hundred day simple moving average is $400.22. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.59 and a current ratio of 1.59. Humana Inc. has a twelve month low of $299.23 and a twelve month high of $541.21.

Humana (NYSE:HUM - Get Free Report) last posted its quarterly earnings data on Thursday, January 25th. The insurance provider reported ($0.11) earnings per share for the quarter, missing the consensus estimate of $0.76 by ($0.87). The firm had revenue of $26.46 billion for the quarter, compared to analyst estimates of $25.47 billion. Humana had a return on equity of 19.44% and a net margin of 2.34%. The business's quarterly revenue was up 17.9% on a year-over-year basis. During the same period in the previous year, the business posted $1.62 EPS. As a group, analysts forecast that Humana Inc. will post 16.06 EPS for the current fiscal year.

Humana Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 26th. Stockholders of record on Friday, June 28th will be issued a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a dividend yield of 1.08%. The ex-dividend date is Friday, June 28th. Humana's payout ratio is 17.86%.

Analyst Ratings Changes

Several research firms recently weighed in on HUM. Cantor Fitzgerald reiterated a "neutral" rating and issued a $391.00 target price on shares of Humana in a research note on Wednesday, April 10th. Royal Bank of Canada reduced their target price on shares of Humana from $507.00 to $415.00 and set an "outperform" rating for the company in a research note on Friday, January 26th. Barclays reduced their target price on shares of Humana from $356.00 to $310.00 and set an "equal weight" rating for the company in a research note on Tuesday, April 2nd. Wells Fargo & Company reduced their target price on shares of Humana from $413.00 to $350.00 and set an "overweight" rating for the company in a research note on Monday, April 8th. Finally, TheStreet cut shares of Humana from a "b" rating to a "c+" rating in a research note on Monday, January 8th. Eleven equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $465.42.

Insider Transactions at Humana

In other news, Director Jorge S. Mesquita acquired 545 shares of the company's stock in a transaction dated Tuesday, February 20th. The stock was bought at an average price of $367.09 per share, with a total value of $200,064.05. Following the completion of the acquisition, the director now owns 2,578 shares in the company, valued at approximately $946,358.02. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 0.32% of the company's stock.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.